MiMedx’s wound care allograft is used in treating neuropathic diabetic foot ulcers and venous stasis ulcers, where in traditional measures have failed to provide a cure.

MiMedx Group chairman and CEO Parker Petit said that the approval by WPS brings the total Medicare Contractors agreeing to reimburse for the company’s EpiFix wound care tissue grafts to six of the nine.

"As we have stated previously, we have aggressively pursued this critical aspect of our reimbursement strategy, and we are very happy to see the results from that initiative continue to expand the geography in which EpiFix® is approved for coverage," Petit added.

MiMedx Group president and COO Bill Taylor said that the documented efficacy and cost-effectiveness of EpiFix is driving the rapid pace at which we are securing approvals from the Medicare Contractors.

"Most recent was the peer-reviewed publication of the compelling results from our randomized controlled clinical trial of patients with diabetic foot ulcers.

"In addition, the results of the crossover study from that clinical trial have been accepted for publication, and over the next few months, we expect several additional clinical studies to be published," Taylor added.

A payment of almost five applications has been approved for each ulcer case.